Could blood thinners stop a second stroke? new trial investigates
NCT ID NCT06486792
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at people over 65 who recently had a stroke with no clear cause. Doctors suspect they may have hidden atrial fibrillation (an irregular heartbeat) not caught in the hospital. The trial compares two treatments: a blood thinner (apixaban) or aspirin, to see which better prevents another stroke or blood clots. About 1,148 participants will be monitored for up to 12 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Apixaban (a blood thinner) or aspirin
- What this could lead to
- If successful, this could show that using blood thinners early after a stroke of unknown cause reduces the risk of another stroke.
- What could go wrong
- This is a Phase 4 trial, but the benefit-risk balance of blood thinners versus aspirin in this specific group is still unproven. Blood thinners carry a risk of bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 1,148 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
65 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Included patients must fulfill the following 4 criteria: 1. patient aged ≥65 years with: 1. recent (\<15 days) cerebral infarction 2. with cerebral ischemia proven on MRI or head-CT 2. with no known atrial fibrillation before stroke and no atrial fibrillation detected during hospital stay (monitoring or telemetry) and no mural thrombus. 3. but with suspected atrial fibrillation: 1. multiple territorial (i.e., in the territory of a cerebral artery or one of its branches) cerebral infarctions in several arterial territories involving both hemispheres, or in the same hemisphere, or in both anterior and posterior circulation, symptomatic or not 2. or a single cerebral infarction and systemic emboli (e.g., renal, splenic, hepatic or mesenteric infarction, peripheral emboli in arm or leg), symptomatic or not 3. or any ischemic stroke with dilation of atrium (\>34 mL/m²) or left atrial spontaneous echocardiographic contrast or LAA velocities \< 40 cm/sec or pro BNP \> 400 pg/mL or left ventricular ejection fraction (LVEF) \< 40% or supraventricular extrasystole ≥ 400/24 h or longest "atrial run" ≥ 20 beats on telemetry 4. or age ≥80 year-old and a single infarction 4. and a plan to detect atrial fibrillation with, long term Holter ECG, wearing device or implantable loop recorder 5. with a Rankin score equal or less than 4 6. patient has signed an informed consent 7. Patient is affiliated to a social security. Exclusion Criteria: 1. Patients with a known cause of stroke, using ASCOD classification A1, C1, S1, O1, D1 2. Symptomatic brain hemorrhage (the mere presence of microbleeds on gradient echo imaging is not an exclusion criteria) 3. Uncontrolled hypertension (following the judgment of the investigator) 4. Clear indication to anticoagulant or antiplatelet therapy 5. Contra-indication to anticoagulant or antiplatelet therapy 6. Intercurrent disease that may interfere with evaluation of the primary end-point or that may prevent follow-up study visits 7. Participation in another interventional clinical trial. 8. Under contraception in case of childbearing potential 9. Patient under guardianship or curatorship
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Bichat Hospital
RECRUITINGParis, Paris, 75018, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a checklist and heart monitor stop repeat strokes?
- Heart hole or stroke trigger? global registry tracks who gets closure and what happens next
- Two ways to quiet a racing heart: trial pits hybrid ablation against standard catheter treatment
- Stroke's hidden heart rhythm clue under investigation
- Zapping the spine while wearing a robotic ankle: a new way to help kids walk?
- Suture device may get heart patients walking sooner after leg vein procedures